Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of nivolumab versus nivolumab + ipilimumab in previously treated unresectable malignant pleural mesothelioma
2015-004475-75Phase 2Completed
- Sponsor
- IFCT
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in pleural mesothelioma comparing Nivolumab monotherapy with Nivolumab + ipilimumab (2 arms). Primary endpoint: Disease control rate. Started Mar 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2015-004475-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004475-75.